Harbor is now

7 Appetite Suppressants Compared to GLP-1 Shots

Appetite suppressants run from short-term prescription pills to fiber, protein and caffeine. Here are seven, each read from its FDA label or NIH evidence, and how GLP‑1 shots prescribed by a clinician compare.

Clinically reviewed
Medically reviewed by Harbor Health TeamMedical Content Team11 min read

The top three

From FDA labels & NIH sources
Our pick

01  Phentermine

A short course, not a long-term plan

02  Phentermine-topiramate

A long-term pill outside the GLP-1 class

10.9%vs 1.6% on placebo

03  Bupropion-naltrexone

A long-term tablet with its own eligibility list

5.4%vs 1.3% on placebo

Where GLP-1 shots fit. GLP-1 shots act on a hormone the Wegovy label calls a physiological regulator of appetite, and the prescription options below are set beside them. A licensed clinician decides whether one is appropriate for you.

Appetite suppressants at a glance

Appetite suppressants are drugs, supplements or foods taken to feel less hungry or full sooner. This list covers four kinds of prescription appetite suppressant pills, two supplement categories and one food.

GLP-1 shots sit beside them as a different kind of medicine. In Harbor's GLP-1 programs, a board-certified physician reviews your health history before anything ships, and the plan is designed to end with a clinician-guided taper and registered-dietitian aftercare. The compounded semaglutide and tirzepatide in those programs are not FDA approved.

OptionWhat it isFDA statusWhat the source reports
PhenterminePrescription stimulant, Schedule IVApproved for a few weeksOnly a fraction of a pound a week more than placebo
Phentermine-topiramate (Qsymia)Prescription capsule, Schedule IVApproved for long-term use10.9% vs 1.6% on placebo at one year, top dose
Bupropion-naltrexone (Contrave)Prescription tabletApproved for long-term use5.4% vs 1.3% on placebo at 56 weeks
Diethylpropion and phendimetrazinePrescription stimulants, Schedule IV and IIIApproved for a few weeksA fraction of a pound a week more than placebo
Glucomannan and other fiberDietary supplementNo FDA review before saleNo significant effect on weight in a 2015 review of six trials
ProteinFoodNot a drug441 fewer calories a day in a 19-person study
Caffeine and green tea extractDrink or dietary supplementNo FDA review before sale as a supplementGreen tea preparations 0.95 kg more than placebo over 12 to 13 weeks, and no significant difference in trials outside Japan

Drug rows come from each current FDA label on DailyMed, mean percent weight change in the label's own trial. Supplement rows come from the NIH Office of Dietary Supplements fact sheet, and the protein row from a 2005 University of Washington study.

Appetite suppressants & how each one works

An appetite suppressant can work on the brain, on the stomach or on neither, depending on which one you mean. The seven below start with the prescription drugs, phentermine through diethylpropion and phendimetrazine, then move to glucomannan, protein, and caffeine with green tea extract.

One detail in the fine print is easy to miss. FDA's labels for phentermine, diethylpropion and phendimetrazine each say it has not been established that appetite suppression is the primary way these drugs work in treating obesity.

A product sold as an over the counter appetite suppressant in supplement form has not been reviewed by FDA first. The NIH Office of Dietary Supplements states that, unlike drugs, dietary supplements do not require premarket review or approval by FDA. Its fact sheet also advises talking with a health care provider before using one, especially with high blood pressure, diabetes, or liver or heart disease. Related: GLP-1 supplements compared.

01

Phentermine

Prescription stimulant, Schedule IV

A few weekslabeled use

Phentermine was first approved in the U.S. in 1959. Its FDA label approves it only as a short-term adjunct, a few weeks, alongside exercise, behavior change and a reduced-calorie diet, for people with a BMI of 30 or more, or 27 or more with other risk factors.

Where it wins

  • The label describes phentermine as a sympathomimetic amine with activity similar to amphetamine
  • In relatively short-term trials, people on drugs of this class lost more weight on average than people on placebo and diet
  • Taken by mouth, with no injections

What it costs you

  • That added loss was only a fraction of a pound a week, in the label's words
  • Schedule IV controlled substance
  • Ruled out by a history of cardiovascular disease, an overactive thyroid, glaucoma, a history of drug abuse, pregnancy or nursing

A short course, not a long-term plan

02

Phentermine-topiramate

Daily capsule, Schedule IV

10.9%vs 1.6% on placebo

Phentermine-topiramate, sold as Qsymia, pairs phentermine with extended-release topiramate. Unlike phentermine alone, it is approved for long-term use with a reduced-calorie diet and more physical activity, in adults and children 12 and older with obesity and in adults with overweight and at least one weight-related condition.

Where it wins

  • In the label's Study 1, adults with a BMI of 35 or more averaged 10.9% weight loss on the top dose vs 1.6% on placebo after one year
  • In Study 2, the 7.5 mg/46 mg dose averaged 7.8% and the top dose 9.8%, vs 1.2% on placebo
  • Per the label, topiramate may act through both appetite suppression and a stronger sense of fullness

What it costs you

  • The label says the precise mechanism is not known
  • Schedule IV, because it contains phentermine
  • Contraindicated in pregnancy, and distributed only by certified pharmacies under a risk program called a REMS

A long-term pill outside the GLP-1 class

03

Bupropion-naltrexone

Extended-release tablet

5.4%vs 1.3% on placebo

Bupropion-naltrexone, sold as Contrave, combines an antidepressant with an opioid antagonist. Nonclinical studies cited on its label suggest the pair acts on the hypothalamus, the brain's appetite regulatory center, and on the mesolimbic dopamine circuit, its reward system.

Where it wins

  • Approved for long-term use in adults with obesity, or with overweight and at least one condition tied to weight
  • In the 56-week COR-I trial, mean weight change was 5.4% on the full dose vs 1.3% on placebo
  • In COR-BMOD, a second label trial, the figures were 8.1% vs 4.9%

What it costs you

  • The label says the exact effects that lead to weight loss are not fully understood
  • Contraindicated with chronic opioid use, a seizure disorder, uncontrolled high blood pressure, and bulimia or anorexia nervosa
  • Not recommended for anyone under 18, per its label

A long-term tablet with its own eligibility list

04

Diethylpropion & phendimetrazine

Stimulants in phentermine's class

A few weekslabeled use

Diethylpropion and phendimetrazine sit in the same drug class as phentermine. Both labels approve them only as a short-term adjunct, a few weeks, to a reduced-calorie plan. The diethylpropion label limits it to people with a BMI of 30 or higher who have not responded to diet or exercise alone.

Where it wins

  • Both are sympathomimetic amines with activity similar to the amphetamines, per their labels
  • Short-term trials of this drug class showed more weight loss on average than placebo and diet

What it costs you

  • On the diethylpropion label, the added loss averages some fraction of a pound a week
  • Diethylpropion is Schedule IV and phendimetrazine is Schedule III
  • The phendimetrazine label says tolerance to its effect develops within a few weeks, and that it should then be stopped

Short-term use only, under a prescriber

05

Glucomannan & other fiber

Soluble fiber supplement

6 trialsno effect on weight

Glucomannan is a soluble fiber from konjac root that can absorb up to 50 times its weight in water. It has been proposed to increase fullness and slow stomach emptying, but the NIH Office of Dietary Supplements calls its effects on weight loss inconsistent.

Where it wins

  • An older meta-analysis of 14 studies found a mean 0.79 kg more loss than placebo over about 5 weeks
  • A review of guar gum, another soluble fiber, concluded that 2 to 5 g increases satiety and cuts snacking between meals

What it costs you

  • A 2015 systematic review of six trials with 293 participants found no significant effect on body weight
  • A 2001 meta-analysis concluded that guar gum is not effective for body weight reduction
  • Dietary supplements do not require premarket review or approval by FDA

Fullness at a meal, not proven weight loss

06

Protein

Food, not a drug

441fewer kcal a day

Protein is the one option here that is already on your plate. In a 2005 University of Washington study, 19 people moved from 15% to 30% of calories from protein with carbohydrate held constant. Satiety rose markedly, and when they could eat freely they took in 441 fewer calories a day.

Where it wins

  • Over the 12 weeks of free eating in that study, average body weight fell 4.9 kg
  • A 2015 review in the American Journal of Clinical Nutrition confirmed a modest satiety effect, including greater perceived fullness after higher-protein meals
  • That review suggests 1.2 to 1.6 g of protein per kg of body weight a day, with at least about 25 to 30 g a meal

What it costs you

  • The same review found no support for an effect on how much people ate at the next meal
  • Longer-term studies were limited and conflicting, which the authors tied mainly to people not keeping to the diet
  • The 2005 study was small, with 19 people on three diets in sequence

The food-first place to start

07

Caffeine & green tea extract

Stimulant & plant extract

0.95 kgmore than placebo

Caffeine and green tea extract appear in many weight-loss supplements, yet the NIH fact sheet does not list appetite as how either one works. It describes caffeine as stimulating the central nervous system and raising thermogenesis and fat oxidation, and green tea as raising energy expenditure and fat oxidation.

Where it wins

  • A 2012 Cochrane Review of 14 trials in 1,562 people found green tea preparations reduced weight by a mean 0.95 kg more than placebo over 12 to 13 weeks
  • A meta-analysis of six trials found caffeine, alone or with catechins, raised energy expenditure compared with placebo

What it costs you

  • In the six Cochrane trials run outside Japan, the difference from placebo was not statistically significant
  • The fact sheet concludes that any effect of green tea is small and not likely to be clinically relevant
  • Habitual caffeine use leads to tolerance and smaller effects

A drink, not an appetite treatment

Prescription appetite suppressants vs GLP-1 shots

Prescription appetite suppressants and GLP-1 shots reach appetite by different routes. The stimulant pills are sympathomimetic amines. GLP-1 medicines activate the receptor for GLP-1, which the Wegovy label calls a physiological regulator of appetite and caloric intake.

Length of use separates them further. The NIDDK prescription medication guide lists six drugs FDA has approved for long-term use, including the weekly shots Wegovy and Zepbound, and notes that medications such as phentermine are approved only for a few weeks.

What the label saysShort-term stimulantsQsymiaContraveBrand GLP-1 shots
How it is takenBy mouthCapsule by mouthTablet by mouthInjection once a week
Labeled length of useA few weeksLong termLong termLong term
Drug classSympathomimetic aminePhentermine plus topiramateOpioid antagonist plus antidepressantGLP-1 receptor agonist (Zepbound also acts on GIP)
Controlled substance scheduleSchedule IV, or III for phendimetrazineSchedule IVNone listedNone listed
Label trial resultA fraction of a pound a week more than placebo10.9% vs 1.6% on placebo, one year5.4% vs 1.3% on placebo, 56 weeksWegovy 14.9% vs 2.4%, 68 weeks. Zepbound 15 mg 20.9% vs 3.1%, 72 weeks

From each current FDA label on DailyMed. These are separate trials with different lengths and populations, not a head-to-head result. The GLP-1 figures are for brand Wegovy and Zepbound. Compounded semaglutide and tirzepatide are not FDA approved and were not the products studied in those trials.

Read the last row with care. A trial average is not a personal forecast.

How to choose an appetite suppressant with a clinician

People searching for how to suppress appetite usually want one answer. A clinician works through several questions in order, and your history settles most of them before your preferences come in.

  1. Whether medication fits at all. NIDDK says a health care professional may prescribe one for an adult with a BMI of 30 or greater, or 27 or greater with a weight-related health problem such as high blood pressure or type 2 diabetes.
  2. What your history rules out. A history of cardiovascular disease excludes phentermine, chronic opioid use excludes Contrave, and pregnancy excludes Qsymia. A personal or family history of medullary thyroid carcinoma or MEN 2 excludes Wegovy and Zepbound.
  3. How long treatment should run. Phentermine, diethylpropion and phendimetrazine are labeled for a few weeks. Qsymia, Contrave and the brand GLP-1 shots are labeled for long-term use.
  4. When to check progress. NIDDK says that if you have not lost at least 5% of your starting weight after 12 weeks on the full dose, your health care professional will probably advise you to stop.
  5. What else you take. NIDDK advises telling your prescriber about supplements and vitamins, and not combining weight-loss medications with other weight-loss products unless they are prescribed.

Food stays in the plan whichever option is chosen. NIDDK is plain that medications do not replace physical activity or healthy eating habits.

NIDDK advises never taking a weight management medication during pregnancy or while planning one. A prescriber checks that, your other medicines and your health history before anything is prescribed. For your own situation, message your Harbor clinician.

GLP-1 shots with Harbor

GLP 1 shots through Harbor are a once-weekly injection you give yourself at home, inside a program designed to end. A board-certified physician reviews your intake before anything ships. When you reach your goal, the plan moves to a structured, clinician-guided taper and registered-dietitian aftercare.

Harbor compounded semaglutide starts at $89 a month and compounded tirzepatide at $119, with medication, clinician care and check-ins in one price and no insurance required. Both are compounded drugs, so they are not FDA approved, and neither was the product tested in the Wegovy or Zepbound trials.

Then there is food noise. A 2023 review in the journal Nutrients calls it a colloquial term for rumination and preoccupation with food, drawn from anecdotal reports by patients and clinicians. The Wegovy label never uses the phrase. It says semaglutide decreases calorie intake and that the effect is likely mediated by affecting appetite. Related reading: how food noise changes on tirzepatide.

The prescription pills on this list stay with an in-person prescriber. Harbor does not prescribe phentermine or other Schedule IV controlled substances, and its FAQ says members who want one are referred to in-person obesity-medicine specialists. The weekly shots ship as a vial with U-100 insulin syringes, with 24/7 access to licensed clinicians for medical questions through the patient portal.

If a GLP-1 is not the right fit, it is not prescribed. The online quiz takes about 90 seconds and is the first step toward a physician review.

This article is for general education and is not medical advice. It is not a substitute for evaluation, diagnosis, or treatment by a licensed clinician. Talk with a qualified clinician about your individual situation.

Harbor is a technology platform. Medical evaluations are conducted by independent, licensed healthcare providers who determine whether treatment is appropriate. Compounded medications are not FDA approved and are not reviewed by the FDA for safety or effectiveness.

Frequently asked questions

Some do, modestly, and it depends on which one. For the short-term prescription pills, the FDA labels answer that people lost only a fraction of a pound a week more than on placebo. Long-term drugs did more in their label trials: Qsymia averaged 10.9% vs 1.6% on placebo at one year, and Contrave 5.4% vs 1.3% at 56 weeks. For supplements, the NIH Office of Dietary Supplements calls the evidence inconclusive and unconvincing.

A natural appetite suppressant is a food or supplement taken to feel fuller, such as protein, a soluble fiber like glucomannan, or green tea. Protein has a small human study behind it: 19 people ate 441 fewer calories a day at 30% protein in 2005. Glucomannan had no significant effect on body weight in a 2015 review of six trials. Supplements also reach the shelf without premarket review or approval by FDA.

In effect, partly, though a GLP-1 is not classed with the older appetite pills. The Wegovy label describes GLP-1 as a physiological regulator of appetite and caloric intake, and says semaglutide decreases calorie intake, likely by affecting appetite. It also delays gastric emptying. Stimulant pills such as phentermine are sympathomimetic amines, a different drug class. A licensed clinician decides whether compounded semaglutide or tirzepatide, which are not FDA approved, is appropriate for you.

Sources

  1. Phentermine hydrochloride tablets label, DailyMed.
  2. Qsymia (phentermine and topiramate extended-release) capsules label, revised 03/2026, DailyMed.
  3. Contrave (naltrexone and bupropion) extended-release tablets label, revised 11/2025, DailyMed.
  4. Diethylpropion hydrochloride tablets label, DailyMed.
  5. Phendimetrazine tartrate tablets label, DailyMed.
  6. Wegovy (semaglutide) injection and tablets label, revised 06/2026, DailyMed.
  7. Zepbound (tirzepatide) injection label, revised 08/2026, DailyMed.
  8. Prescription medications to treat overweight & obesity, NIDDK.
  9. Dietary supplements for weight loss, health professional fact sheet, NIH Office of Dietary Supplements, updated May 18, 2022.
  10. Weigle DS et al. A high-protein diet induces sustained reductions in appetite, ad libitum caloric intake, and body weight. Am J Clin Nutr. 2005.
  11. Leidy HJ et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015.
  12. Hayashi D et al. What is food noise? A conceptual model of food cue reactivity. Nutrients. 2023.
  13. FDA's concerns with unapproved GLP-1 drugs used for weight loss.
  • GLP-1 Medications

    Six options when weekly Wegovy is out of reach: compounded semaglutide and tirzepatide, which are not FDA approved, plus Zepbound, the Wegovy pill, Foundayo and Saxenda. What each one is and how a clinician chooses.

    By Harbor Health Team

  • GLP-1 Medications

    Both routes now include GLP-1 medicines. One is a shot once a week, the other a tablet every day, sometimes on an empty stomach. Here is how the labels compare, and where a clinician fits.

    By Harbor Health Team

  • GLP-1 Medications

    Seven brand GLP 1 shots described from their FDA labels, plus compounded semaglutide and tirzepatide, which are not FDA approved. What each treats, how often you inject it and how to choose.

    By Harbor Health Team